309 related articles for article (PubMed ID: 36878969)
21. Identification of the immune cell infiltration landscape in pancreatic cancer to assist immunotherapy.
Wang Z; Zou W; Wang F; Zhang G; Chen K; Hu M; Liu R
Future Oncol; 2021 Nov; 17(31):4131-4143. PubMed ID: 34346253
[TBL] [Abstract][Full Text] [Related]
22. Single-cell RNA-seq highlights intra-tumoral heterogeneity and malignant progression in pancreatic ductal adenocarcinoma.
Peng J; Sun BF; Chen CY; Zhou JY; Chen YS; Chen H; Liu L; Huang D; Jiang J; Cui GS; Yang Y; Wang W; Guo D; Dai M; Guo J; Zhang T; Liao Q; Liu Y; Zhao YL; Han DL; Zhao Y; Yang YG; Wu W
Cell Res; 2019 Sep; 29(9):725-738. PubMed ID: 31273297
[TBL] [Abstract][Full Text] [Related]
23. Identification and validation of the cellular senescence-related molecular subtypes of triple negative breast cancer via integrating bulk and single-cell RNA sequencing data.
Ju G; Zeng K; Lu L; Diao H; Wang H; Li X; Zhou T
Am J Cancer Res; 2023; 13(2):569-588. PubMed ID: 36895975
[TBL] [Abstract][Full Text] [Related]
24. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma.
Wang WQ; Liu L; Xu HX; Wu CT; Xiang JF; Xu J; Liu C; Long J; Ni QX; Yu XJ
Br J Surg; 2016 Aug; 103(9):1189-99. PubMed ID: 27256393
[TBL] [Abstract][Full Text] [Related]
25. Gene expression profiling of 1200 pancreatic ductal adenocarcinoma reveals novel subtypes.
Zhao L; Zhao H; Yan H
BMC Cancer; 2018 May; 18(1):603. PubMed ID: 29843660
[TBL] [Abstract][Full Text] [Related]
26. Identification and validation of cancer-associated fibroblast-related subtypes and the prognosis model of biochemical recurrence in prostate cancer based on single-cell and bulk RNA sequencing.
Li T; Zhou Z; Xie Z; Fan X; Zhang Y; Zhang Y; Song X; Ruan Y
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11379-11395. PubMed ID: 37369799
[TBL] [Abstract][Full Text] [Related]
27. A robust 6-mRNA signature for prognosis prediction of pancreatic ductal adenocarcinoma.
Zhou C; Zhao Y; Yin Y; Hu Z; Atyah M; Chen W; Meng Z; Mao H; Zhou Q; Tang W; Wang P; Li Z; Weng J; Bruns C; Popp M; Popp F; Dong Q; Ren N
Int J Biol Sci; 2019; 15(11):2282-2295. PubMed ID: 31595147
[TBL] [Abstract][Full Text] [Related]
28. Exploring KRAS-mutant pancreatic ductal adenocarcinoma: a model validation study.
Yang F; He Y; Ge N; Guo J; Yang F; Sun S
Front Immunol; 2023; 14():1203459. PubMed ID: 38268915
[TBL] [Abstract][Full Text] [Related]
29. Glycolysis-Related Gene Expression Profiling Screen for Prognostic Risk Signature of Pancreatic Ductal Adenocarcinoma.
Song W; He X; Gong P; Yang Y; Huang S; Zeng Y; Wei L; Zhang J
Front Genet; 2021; 12():639246. PubMed ID: 34249078
[No Abstract] [Full Text] [Related]
30. Comprehensive analysis of KLF family reveals KLF6 as a promising prognostic and immune biomarker in pancreatic ductal adenocarcinoma.
Lin J; Liu P; Sun K; Jiang L; Liu Y; Huang Y; Liu J; Shi M; Zhang J; Wang T; Shen B
Cancer Cell Int; 2024 May; 24(1):177. PubMed ID: 38773440
[TBL] [Abstract][Full Text] [Related]
31. Transcriptomic Analysis of Laser Capture Microdissected Tumors Reveals Cancer- and Stromal-Specific Molecular Subtypes of Pancreatic Ductal Adenocarcinoma.
Birnbaum DJ; Begg SKS; Finetti P; Vanderburg C; Kulkarni AS; Neyaz A; Hank T; Tai E; Deshpande V; Bertucci F; Birnbaum D; Lillemoe KD; Warshaw AL; Mino-Kenudson M; Fernandez-Del Castillo C; Ting DT; Liss AS
Clin Cancer Res; 2021 Apr; 27(8):2314-2325. PubMed ID: 33547202
[TBL] [Abstract][Full Text] [Related]
32. A Ductal-Cell-Related Risk Model Integrating Single-Cell and Bulk Sequencing Data Predicts the Prognosis of Patients With Pancreatic Adenocarcinoma.
Wang X; Dou X; Ren X; Rong Z; Sun L; Deng Y; Chen P; Li Z
Front Genet; 2021; 12():763636. PubMed ID: 35047000
[TBL] [Abstract][Full Text] [Related]
33. Construction and validation of a novel immunological model to predict prognosis in pancreatic ductal adenocarcinoma.
Liu J; He M
Int Immunopharmacol; 2024 Jun; 134():112266. PubMed ID: 38761784
[TBL] [Abstract][Full Text] [Related]
34. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
35. Survival-Associated Alternative Messenger RNA Splicing Signatures in Pancreatic Ductal Adenocarcinoma: A Study Based on RNA-Sequencing Data.
Zhou YJ; Zhu GQ; Zhang QW; Zheng KI; Chen JN; Zhang XT; Wang QW; Li XB
DNA Cell Biol; 2019 Nov; 38(11):1207-1222. PubMed ID: 31483163
[TBL] [Abstract][Full Text] [Related]
36. Integrated analysis of single-cell and bulk RNA sequencing identifies a signature based on macrophage marker genes involved in prostate cancer prognosis and treatment responsiveness.
Li X; Zheng C; Xue X; Wu J; Li F; Song D; Li X
Funct Integr Genomics; 2023 Apr; 23(2):115. PubMed ID: 37010617
[TBL] [Abstract][Full Text] [Related]
37. Novel prognostic gene signature for pancreatic ductal adenocarcinoma based on hypoxia.
Ren M; Feng L; Zong R; Sun H
World J Surg Oncol; 2023 Aug; 21(1):257. PubMed ID: 37605192
[TBL] [Abstract][Full Text] [Related]
38. Values of a novel pyroptosis-related genetic signature in predicting outcome and immune status of pancreatic ductal adenocarcinoma.
Xu X; Liang JH; Li JH; Xu QC; Yin XY
Gastroenterol Rep (Oxf); 2022; 10():goac051. PubMed ID: 36196256
[TBL] [Abstract][Full Text] [Related]
39. A novel refined pyroptosis and inflammasome-related genes signature for predicting prognosis and immune microenvironment in pancreatic ductal adenocarcinoma.
Zuo J; Yi C; Chen Z; Zhou B; Yang T; Lin J
Sci Rep; 2022 Nov; 12(1):18384. PubMed ID: 36319832
[TBL] [Abstract][Full Text] [Related]
40. Systematic Analysis of Alternative Splicing Landscape in Pancreatic Adenocarcinoma Reveals Regulatory Network Associated with Tumorigenesis and Immune Response.
Lu J; Wei S; Lou J; Yin S; Zhou L; Zhang W; Zheng S
Med Sci Monit; 2020 Jul; 26():e925733. PubMed ID: 32706768
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
